The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABEO | -15.11% | -87.5% | -34.02% | -100% |
| S&P | +11.96% | +82.68% | +12.81% | +994% |
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
This company is making excellent progress on its treatment for a very rare and serious skin disorder.
The small-cap company announced the pricing of a public stock offering.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$1.38M | -90.6% |
| Gross Margin | -117.00% | 0.0% |
| Market Cap | $270.75M | -1.1% |
| Market Cap / Employee | $1.99M | 0.0% |
| Employees | 136 | 61.9% |
| Net Income | -$5.16M | 82.9% |
| EBITDA | -$23.13M | -58.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $83.22M | 418.1% |
| Inventory | 4.8 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.12M | -14.2% |
| Short Term Debt | $8.99M | 63.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 46.83% | 122.9% |
| Return On Invested Capital | -146.08% | -12.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.71M | -87.6% |
| Operating Free Cash Flow | -$21.19M | -73.2% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 9.00 | 4.53 | - | ||
| Price to Book | 5.28 | 4.93 | 6.72 | 1.65 | -53.99% |
| Price to Sales | 36.58 | 56.58 | 946.30 | 716.00 | - |
| Price to Tangible Book Value | 5.28 | 4.93 | 6.72 | 1.65 | -53.99% |
| Enterprise Value to EBITDA | -11.28 | -9.33 | -8.02 | -4.46 | -69.97% |
| Return on Equity | -216.6% | -271.8% | 48.3% | 75.9% | -136.23% |
| Total Debt | $23.05M | $23.98M | $24.08M | $24.11M | 4.32% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
